Cellectar Biosciences Inc. NEW
$2.41 -$0.06 (-2.43%) 1D After hoursKey Metrics
The Story So Far
LAST 6 MONTHS PRIMARY SOURCES ONLY-
Jul 16
Money rotated out of high-beta cohorts market-wide.
High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.
RECEIPT: ROTATION GAUGE, LIVE -
Jun 18
The stock moved +12.5% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Jun 18 -
Jun 12
From its May 6 high, the share price fell 37%.
Peak close $3.53 on May 6; trough close $2.23 on Jun 12. The drawdown is the fact — the chapters around it are the context.
RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -37% -
May 5
The stock moved +12.4% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, May 5
The story updates itself as events post · The wolf reports; you decide
Snapshot
About Cellectar Biosciences Inc. NEW
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer.
Wolf Grade COMING SOON
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.